Possible Use of Ganoderma Mushroom Extracts for the Treatment of Some Chronic Risk Factors Associated with Severe Covid-19

Ohimain Ei
{"title":"Possible Use of Ganoderma Mushroom Extracts for the Treatment of Some Chronic Risk Factors Associated with Severe Covid-19","authors":"Ohimain Ei","doi":"10.23880/vij-16000254","DOIUrl":null,"url":null,"abstract":"The novel coronavirus (SARS-CoV-2) emerged in Wuhan, China in December 2019 causing the coronavirus disease 2019 (COVID-19). The disease has caused a pandemic that had disrupted social and economic life globally. Intense research is ongoing to understand the nature of the virus and pathogenesis as well as the development of drugs and vaccines. Ample evidence suggests that the elderly people, those with pre-existing chronic medical conditions, such as lung disease, heart disease, diabetes, obesity, chronic kidney disease, compromised immunity and even men may be at higher risk of serious illness and intensive care. The virus tends to trigger the over-production of pro-inflammatory cytokines, which results in multiorgan damage, resulting in death. Following this review, we proposed the use of Ganoderma mushroom extracts, which have certain properties relevant to the management of COVID-19 complications including anti-inflammatory, antiviral, immune modulatory, and antioxidant, anti-aging and multiorgan protection. Most of this research has been done on rodent models with few clinical trials. Since, the mushroom is generally regarded as safe (GRAS) and have been used for centuries in Asian traditional medicine, we recommend the use of this mushroom in the management of the disease including as active ingredients in COVID-19 drugs, and alternatives to synthetic drugs, health supplements, adjuvant therapy or functional foods.","PeriodicalId":334586,"journal":{"name":"Virology & Immunology Journal","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virology & Immunology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23880/vij-16000254","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

The novel coronavirus (SARS-CoV-2) emerged in Wuhan, China in December 2019 causing the coronavirus disease 2019 (COVID-19). The disease has caused a pandemic that had disrupted social and economic life globally. Intense research is ongoing to understand the nature of the virus and pathogenesis as well as the development of drugs and vaccines. Ample evidence suggests that the elderly people, those with pre-existing chronic medical conditions, such as lung disease, heart disease, diabetes, obesity, chronic kidney disease, compromised immunity and even men may be at higher risk of serious illness and intensive care. The virus tends to trigger the over-production of pro-inflammatory cytokines, which results in multiorgan damage, resulting in death. Following this review, we proposed the use of Ganoderma mushroom extracts, which have certain properties relevant to the management of COVID-19 complications including anti-inflammatory, antiviral, immune modulatory, and antioxidant, anti-aging and multiorgan protection. Most of this research has been done on rodent models with few clinical trials. Since, the mushroom is generally regarded as safe (GRAS) and have been used for centuries in Asian traditional medicine, we recommend the use of this mushroom in the management of the disease including as active ingredients in COVID-19 drugs, and alternatives to synthetic drugs, health supplements, adjuvant therapy or functional foods.
灵芝提取物可能用于治疗与严重Covid-19相关的一些慢性危险因素
2019年12月,新型冠状病毒(SARS-CoV-2)在中国武汉出现,引发了2019年冠状病毒病(COVID-19)。这种疾病造成了一场大流行,扰乱了全球的社会和经济生活。目前正在进行深入研究,以了解病毒的性质和发病机制以及药物和疫苗的开发。大量证据表明,老年人、先前患有慢性疾病的人,如肺病、心脏病、糖尿病、肥胖、慢性肾病、免疫力受损的人,甚至男性,患严重疾病和重症监护的风险可能更高。这种病毒往往会引发促炎细胞因子的过度产生,从而导致多器官损伤,从而导致死亡。根据这篇综述,我们提出使用灵芝提取物,它具有抗炎、抗病毒、免疫调节、抗氧化、抗衰老和多器官保护等与COVID-19并发症管理相关的特性。大多数研究都是在啮齿动物模型上进行的,很少有临床试验。由于这种蘑菇通常被认为是安全的(GRAS),并且在亚洲传统医学中已使用了几个世纪,因此我们建议在疾病管理中使用这种蘑菇,包括作为COVID-19药物的活性成分,以及合成药物、保健品、辅助治疗或功能食品的替代品。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信